Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTER-SOX: Serplulimab + SOX vs SOX in Adjuvant Therapy for Gastric/GEJ Adenocarcinoma
NCT07772557Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2031
01
Overview
A Phase 2 trial of serplulimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07772557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772557.